Key result
The mean elimination half-life of a single 2-mg oral dose of pimozide was 66 hours in children with Tourette's syndrome compared with 111 hours in adults.
Why the study?
Does the pharmacokinetics of pimozide differ between adults and children with Tourette's syndrome?
Observational (n=11)
Does the pharmacokinetics of pimozide differ between adults and children with Tourette's syndrome?
The elimination half-life of pimozide is shorter in children than in adults with Tourette's syndrome, highlighting the need for age-specific pharmacokinetic considerations.
May support age-specific pimozide dosing considerations; leaves open validation in prospective pediatric PK trials.
Pimozide is a neuroleptic drug with dopamine receptor and calcium channel blocking activity that is used in the treatment of Tourette's syndrome. A comparison of the pharmacokinetics of pimozide was made in children and adults with Tourette's syndrome. Seven adults (ages 23-39) and four children (ages 6-13) received a single 2-mg oral dose of pimozide and a minimum of nine blood samples were collected over a four-day period. Mean elimination half-life of pimozide in children was 66 hours compared with 111 hours in adults with Tourette's syndrome. Significant interindividual variability of pimozide pharmacokinetics was found in both adults and children with Tourette's syndrome. The pharmacokinetics of pimozide in patients with Tourette's syndrome differs from that reported in adult populations with chronic schizophrenia.
No takes yet. Share an insight, caveat, or question.
Sallee et al. (1987) conducted an observational in Tourette's syndrome (n=11). Pimozide vs. Adults (compared to children) was evaluated on Mean elimination half-life. The mean elimination half-life of a single 2-mg oral dose of pimozide was 66 hours in children with Tourette's syndrome compared with 111 hours in adults.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: